Renata Casseb de Souza Carboni1, Gustavo Luiz Behrens Pinto1, Samuel Katsuyuki Shinjo2. 1. Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3° andar, sala 3184 - Cerqueira César. CEP: 01246-903, Sao Paulo, Brazil. 2. Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3° andar, sala 3184 - Cerqueira César. CEP: 01246-903, Sao Paulo, Brazil. samuel.shinjo@usp.br.
Abstract
BACKGROUND: The protein chitinase-3-like-1 (YKL-40) is rarely analyzed in patients with myositis. Therefore, we aimed to evaluate YKL-40 serum levels; correlate them with laboratory and clinical parameters, disease status, and treatment schemes; and analyze the YKL-40 expression in the muscle tissues of patients with antisynthetase syndrome (ASSD). METHODS: This cross-sectional single-center study included 64 adult patients with ASSD who were age-, gender-, and ethnicity-matched to 64 healthy control individuals. Their YKL-40 serum levels were analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA) kit method, while YKL-40 expression in muscle tissues was analyzed using an immunohistochemical technique. Disease status was assessed using the International Myositis Assessment and Clinical Studies Group (IMACS) set scores. RESULTS: The patients' mean age was 44.8 ± 11.8 years, and median disease duration was 1.5 (0.0-4.0) years. These patients were predominantly female (82.8%) and Caucasian (73.4%). Most patients had stable disease. The median YKL-40 serum level was significantly higher in patients with ASSD when compared to the healthy individuals: 538.4 (363.4-853.1) pg/mL versus 270.0 (201.8-451.9) pg/mL, respectively; P < 0.001. However, YKL-40 serum levels did not correlate with any clinical, laboratory, disease status, or therapeutic parameters (P > 0.050), except tumor necrosis factor alpha (TNF-α) serum levels (Spearman's correlation, rho = 0.382; P = 0.007). YKL-40 was highly expressed by inflammatory cells found in muscle biopsy specimens. CONCLUSIONS: High YKL-40 serum levels were observed in patients with ASSD and correlated positively with TNF-α serum levels. Moreover, YKL-40 was expressed by the inflammatory cells of the muscle tissue.
BACKGROUND: The protein chitinase-3-like-1 (YKL-40) is rarely analyzed in patients with myositis. Therefore, we aimed to evaluate YKL-40 serum levels; correlate them with laboratory and clinical parameters, disease status, and treatment schemes; and analyze the YKL-40 expression in the muscle tissues of patients with antisynthetase syndrome (ASSD). METHODS: This cross-sectional single-center study included 64 adult patients with ASSD who were age-, gender-, and ethnicity-matched to 64 healthy control individuals. Their YKL-40 serum levels were analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA) kit method, while YKL-40 expression in muscle tissues was analyzed using an immunohistochemical technique. Disease status was assessed using the International Myositis Assessment and Clinical Studies Group (IMACS) set scores. RESULTS: The patients' mean age was 44.8 ± 11.8 years, and median disease duration was 1.5 (0.0-4.0) years. These patients were predominantly female (82.8%) and Caucasian (73.4%). Most patients had stable disease. The median YKL-40 serum level was significantly higher in patients with ASSD when compared to the healthy individuals: 538.4 (363.4-853.1) pg/mL versus 270.0 (201.8-451.9) pg/mL, respectively; P < 0.001. However, YKL-40 serum levels did not correlate with any clinical, laboratory, disease status, or therapeutic parameters (P > 0.050), except tumor necrosis factor alpha (TNF-α) serum levels (Spearman's correlation, rho = 0.382; P = 0.007). YKL-40 was highly expressed by inflammatory cells found in muscle biopsy specimens. CONCLUSIONS: High YKL-40 serum levels were observed in patients with ASSD and correlated positively with TNF-α serum levels. Moreover, YKL-40 was expressed by the inflammatory cells of the muscle tissue.
Authors: Miguel A González-Gay; Carlomaurizio Montecucco; Albert Selva-O'Callaghan; Ernesto Trallero-Araguas; Ovynd Molberg; Helena Andersson; Jorge Rojas-Serrano; Diana Isabel Perez-Roman; Jutta Bauhammer; Christoph Fiehn; Rossella Neri; Simone Barsotti; Hannes M Lorenz; Andrea Doria; Anna Ghirardello; Florenzo Iannone; Margherita Giannini; Franco Franceschini; Ilaria Cavazzana; Konstantinos Triantafyllias; Maurizio Benucci; Maria Infantino; Mariangela Manfredi; Fabrizio Conti; Andreas Schwarting; Giandomenico Sebastiani; Annamaria Iuliano; Giacomo Emmi; Elena Silvestri; Marcello Govoni; Carlo Alberto Scirè; Federica Furini; Francisco Javier Lopez-Longo; Julia Martínez-Barrio; Marco Sebastiani; Andreina Manfredi; Javier Bachiller-Corral; Walter Alberto Sifuentes Giraldo; Marco A Cimmino; Claudio Cosso; Alessandro Belotti Masserini; Giovanni Cagnotto; Veronica Codullo; Mariaeva Romano; Giuseppe Paolazzi; Raffaele Pellerito; Lesley Ann Saketkoo; Norberto Ortego-Centeno; Luca Quartuccio; Alberto Batticciotto; Elena Bartoloni Bocci; Roberto Gerli; Christof Specker; Elena Bravi; Carlo Selmi; Simone Parisi; Fausto Salaffi; Federica Meloni; Enrico Marchioni; Alberto Pesci; Giulia Dei; Marco Confalonieri; Paola Tomietto; Laura Nuno; Francesco Bonella; Nicolò Pipitone; Antonio Mera-Valera; Nair Perez-Gomez; Simone Gerzeli; Raquel Lopez-Mejias; Carlo Jorge Matos-Costa; Jose Antonio Pereira da Silva; José Cifrian; Claudia Alpini; Ignazio Olivieri; María Ángeles Blázquez Cañamero; Ana Belén Rodriguez Cambrón; Santos Castañeda; Lorenzo Cavagna Journal: Clin Exp Rheumatol Date: 2017-07-26 Impact factor: 4.473
Authors: Chun Geun Lee; Carla A Da Silva; Charles S Dela Cruz; Farida Ahangari; Bing Ma; Min-Jong Kang; Chuan-Hua He; Seyedtaghi Takyar; Jack A Elias Journal: Annu Rev Physiol Date: 2011 Impact factor: 19.318
Authors: F De Ceuninck; S Gaufillier; A Bonnaud; M Sabatini; C Lesur; P Pastoureau Journal: Biochem Biophys Res Commun Date: 2001-07-27 Impact factor: 3.575